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Innate immune responseThe Toll-like receptors (TLRs) are critical components of the innate immune system that regulate immune
recognition in part through NF-jB activation. A human cell-based high throughput screen (HTS) revealed
substituted 4-aminoquinazolines to be small molecular weight activators of NF-jB. The most potent hit
compound predominantly stimulated through the human TLR4/MD2 complex, and had less activity with
the mouse TLR4/MD2. There was no activity with other TLRs and the TLR4 activation was MD-2 depen-
dent and CD14 independent. Synthetic modiﬁcations of the quinazoline scaffold at the 2 and 4 positions
revealed trends in structure–activity relationships with respect to TLR dependent production of the NF-
jB associated cytokine IL-8 in human peripheral blood mononuclear cells, as well as IL-6 in mouse
antigen presenting cells. Furthermore, the hit compound in this series also activated the interferon
signaling pathway resulting in type I interferon production. Substitution at the O-phenyl moiety with
groups such as bromine, chlorine and methyl resulted in enhanced immunological activity. Computa-
tional studies indicated that the 4-aminoquinazoline compounds bind primarily to human MD-2 in the
TLR4/MD-2 complex. These small molecules, which preferentially stimulate human rather than mouse
innate immune cells, may be useful as adjuvants or immunotherapeutic agents.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).The ﬁrst line of defense against microbial pathogens such as
viruses, bacteria, fungi and protozoa is governed by the innate
immune response, which includes barrier tissues and leukocytes.
Many innate signaling pathways converge on the NF-jB family of
transcription factors,1,2 which are critical in the regulation of these
responses. A small molecular weight molecule that is an effective
NF-jB activator could be incorporated into vaccine adjuvants as
an innate immune activator. Adjuvants are added to antigens in
vaccines to augment adaptive immune responses to poorly immu-
nogenic antigens, and to increase protective antibody titers in at
risk populations due to age (infants and the elderly), or disease
(diabetes, liver failure). Adjuvants also facilitate the use of smaller
doses of antigen, and enable effective immunization with fewer
booster immunizations.3 Development of small molecular weight
non-lipid ligands that are reactive in human cells might have sev-
eral advantages to address different immunological requirements
for vaccines or immune therapeutics.As part of our studies on small molecules that can activate NF-
jB signaling, we conducted a high through-put screening (HTS)
campaign in which a commercially available library of over
170,000 compounds was screened in a human monocyte cell-
based NF-jB activation assay. By utilizing a cell based assay we
theorized that we could identify small molecules that activated
NF-jB through a broad range of mechanisms. Following the cluster
enrichment analysis,4 225 compounds were selected for further
in vitro biological evaluation involving cytokine induction assays
in primary cells, including human peripheral blood mononuclear
cells (hPBMC), mouse splenocytes, mouse bone marrow derived
dendritic cells (mBMDC) and mouse bone marrow derived macro-
phages (mBMDM).5 These cells were incubated in triplicate with
each of the 225 compounds at a single concentration (1 lM for
splenocytes and BMDC, 5 lM for all other mouse cells, and 5 lM
for human cells) and the supernatants were tested for the presence
of NF-jB dependent cytokines, IL-8 or IL-6, released from the
human or mouse cells, respectively. Thirty-nine of the 225 com-
pounds stimulated the human and mouse cells to secrete IL-8 or
4932 A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938IL-6 above the detectable limit. To further conﬁrm activity, these
compounds were repurchased and retested by stimulating hPBMC
and mBMDC with titrated doses and assaying for IL-8 and IL-6,
respectively.
Four structurally diverse library scaffolds were identiﬁed in
these cytokine assays as having reproducible responses. Among
these scaffolds, the substituted 4-aminoquinazolines emerged as
the most potent class of compounds in activating human cells. As
the Toll-like receptors (TLRs) are the most well understood and
studied family of innate immune receptors these receptors were
considered as likely targets for the HTS hit compounds. A few
examples of pathogen-associated molecular patterns that are
natural TLR ligands and their corresponding TLRs include: lipopep-
tides (TLR2), double-stranded RNA (TLR3), lipopolysaccharide (LPS,
TLR4),6 bacterial ﬂagellin (TLR5), guanine and uridine-rich single-
stranded RNA (TLR7, 8), and hypo-methylated CpG rich DNA
(TLR9).7 The speciﬁc innate receptor for the leading hit compound
of the 4-aminoquinazolines was determined using primary cells
from genetically modiﬁed mice, and mouse and human TLR repor-
ter cells. Here we report our discovery and initial structure–activity
relationship (SAR) studies of the substituted 4-aminoquinazolines
class of ligands and their characterization as TLR4/MD-2 agonists.Figure 1. Structure of hit compound 1a.
Figure 2. Compound 1a is a TLR4 speciﬁc ligand that activates NFjB in a TLR4/MD-2-de
TLR5, TLR7, TLR8, and TLR9 HEK 293 Blue cells or NFjB/SEAPorter cells were incubated w
culture supernatants using SEAPorter assay kit. Data shown are mean ± SEM of triplica
results. ⁄Denotes p <0.05 was considered signiﬁcant compared to the vehicle control usin
deﬁcient for TLR4 (B), MD-2 or CD14 (C) were stimulated with 1a (10 lM). IL-6 levels in
cells were incubated with 10 lM 1a or 10 ng/mL LPS in the presence or absence of TLR4
evaluated by SEAP secretion in the culture supernatants. ⁄Denotes p <0.05 considered
testing. (E) Human PBMC were incubated with 1a alone or 1a with polymyxin B (10 lg/m
are mean ± SEM of triplicates and representative of two independent experiments show
hPBMC. ⁄Denotes p <0.05 compared to LPS without polymyxin B.Within this scaffold cluster, the leading hit from the initial primary
and secondary screens was a nitrophenyl-containing 4-aminoqui-
nazoline bearing a phenoxy group on the nitrophenyl moiety
(Fig. 1).
To identify the target receptor, we used HEK293 cells stably
transfected with the following human TLRs (TLR2, TLR3, TLR4/
MD-2/CD14, TLR5, TLR7, TLR8 or TLR9) along with an NF-jB activa-
tion reporter producing Secreted alkaline phosphatase (SEAP,
Fig. 2A). Among the tested TLR transfected cells, only those
expressing TLR4/MD-2/CD14 responded to hit compound 1a, as
shown in Figure 2A. To further conﬁrm that TLR4 was indeed the
receptor, compound 1a was assayed for IL-6 production in
mBMDCs from wild type and TLR4 deﬁcient mice (Fig. 2B). Genetic
disruption of TLR4 completely abrogated IL-6 secretion induced by
compound 1a.
TLR4 signals through two distinct pathways, leading respec-
tively to NF-jB dependent cytokines and type I interferon (IFN)
production. Several naturally occurring TLR4 ligands and MPLA
have been reported to require CD14 to activate the IFN regulatory
pathway.8 The hTLR4 reporter cell line (Fig. 2A) also overexpresses
hMD-2 and hCD14, which are TLR4 accessory proteins.9,10 Com-
pound 1a, however, was not dependent on CD14, but dependent
on MD-2 for IL-6 production, as demonstrated using mBMDC
genetically deﬁcient for CD14 or MD-2 (Fig. 2C).
The binding of compound 1a to the TLR4/MD-2/CD14 complex
was further conﬁrmed using a competitive antagonist for the TLR4
binding complex, LPS-RS (LPS from Rhodobacter sphaeroides).11
LPS-RS inhibited NF-jB activation in hTLR4/MD-2/CD14 transfec-
toma cells induced by compound 1a in a dose dependent manner,
indicating that compound 1a bound to the TLR4 complex
(Fig. 2D). Since TLR4/MD-2/CD14 was the receptor complex for
the active compounds in this series, it was important to rule out
the possibility that activity might have been caused by LPS contam-
ination. Therefore, compound 1a (and all active derivatives) werependent, but CD14-independent manner. (A) Human TLR2, TLR3, TLR4/MD-2/CD14,
ith 1a (10 lM) for 20–24 h, and activation was evaluated by SEAP secretion in the
tes and representative of two to three independent experiments showing similar
g Student’s t test. (B–D) mBMDC prepared from wild type mice or mice genetically
the culture supernatant were determined by ELISA. (D) Human TLR4 transfectoma
antagonist LPS-RS (12, 111, 1000 ng/mL). Activation of the TLR4/NFjB pathway was
as signiﬁcant compared to vehicle using one way ANOVA with Dunnett’s post hoc
L) overnight. IL-8 in the culture supernatants was measured by ELISA. Data shown
ing similar results. (F) Polymyxin B supressed the LPS-induced release of IL-8 in
A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938 4933assayed for LPS (endotoxin) levels using a commercially available
detection system and found to contain less than 2 EU/lmol of endo-
toxin. To further exclude contamination, compound 1awas re-syn-
thesized according to Scheme 1. Both samples of compound 1a
displayed indistinguishable physicochemical and biological proper-
ties, indicating that the positive biological activity was not due to
LPS or another contaminant. Furthermore, the IL-8 inducing ability
of compound 1a was not reduced when assayed in the presence of
polymyxin B, an LPS binding agent (Fig. 2E) although the same con-
centration of polymyxin B signiﬁcantly suppressed IL-8 release by
LPS stimulation (Fig. 2F).
The engagement by active compounds, such as 1a, of the TLR4/
MD-2/CD14 complex may result in signaling through the two path-
ways mentioned above. To evaluate whether the type I IFN path-
way was activated, hPBMC were incubated with compound 1a or
with LPS or vehicle overnight. The release of type I IFN in the cul-
ture supernatants was then determined in a type I IFN reporter cell
assay. Compound 1a was found to induce the release of type I IFN
comparable to that of LPS (Fig. 3A).
To evaluate whether treatment of DCs with this compound can
induce maturation in these cells, mBMDC prepared from wild type
or TLR4 deﬁcient mice were exposed to compound 1a and then
assayed for expression of co-stimulatory molecules CD40, CD80,
and CD86 in the CD11c+ population (Fig. 3B). The expression of all
three co-stimulatory molecules was increased in the wild type cells
treatedwith compound 1a,but not in the TLR4 deﬁcient cells. Induc-
tion of co-stimulatory molecules by compound 1a was also con-
ﬁrmed in human PBMC. After incubation of PBMC with compound
1a overnight, increased expression of CD80 and CD83 was observed
in the DC-enriched (CD11c+HLA-DR+) gated population (Fig. 3C).SchemeThe original HTS of the compound library was conducted using
THP-1 cells, a human monocytic leukemia cell line, wherein four
scaffolds of active compounds were identiﬁed. For further in vivo
immunological studies, mouse models are commonly used. It was
therefore of interest to determine the relative level of immunoac-
tivity in both mouse and human cells for the 4-aminoquinazo-
lines. To examine this, RAW264.7 cells (a mouse macrophage
cell line) or THP-1 cells, both containing a Fluorescence Reso-
nance Energy Transfer (FRET) b-lactamase reporter gene construct
downstream of an NF-jB promoter sequence, were incubated
with graded concentrations of compound 1a for 18 h. The levels
of NF-jB activation were determined, normalized to the level
induced by LPS and expressed as percent activation (Fig. 4A).
The hit compound 1a is signiﬁcantly more potent in human
THP-1 versus mouse RAW264.7 cells. Cytokine induction was
evaluated by exposing mBMDC or hPBMC to graded concentra-
tions of compound 1a and levels of IL-6 or IL-8, respectively, were
determined by ELISA (Fig. 4B and C). Results show that even at
concentrations below 1 lM, compound 1a was able to induce
detectable levels of IL-8 by hPBMC whereas higher concentrations
were required to induce detectable levels of IL-6 by mBMDC, thus
supporting the notion that the active hit compound in this class is
more potent in human cells than in mouse cells. The viability of
mouse BMDC and human PBMC following 18 h incubation with
compound 1a (10 lM) was 117 ± 2.6% and 112 ± 2.1% by MTT
assay, respectively, indicating that the lower activity of
compound 1a was not due to its cytotoxicity. In fact, in vitro
studies using BMDM prepared from transgenic mice12 that were
genetically altered to express human TLR4/MD-2 and deﬁcient
for murine TLR4/MD-2 showed that compounds 1a and 1g in this1.
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Figure 3. Compound 1a induces type I IFN and expression of co-stimulatory molecules. (A) Human PBMC were incubated with 1a (10 lM), LPS (10 ng/mL), or vehicle
overnight. The release of type I IFN in the culture supernatants was measured by luciferase release in L929-ISRE reporter cells. Data shown are mean ± SEM of triplicates. (B)
1a- or vehicle- treated wild type or Tlr4/mBMDC were stained for CD11c and either CD40, CD80, or CD86. The expression levels of CD40, CD80, or CD86 were evaluated in
the gated CD11c+ population. DMSO 0.5% served as the vehicle control. (C) Human PBMC were incubated with compound 1a (5 lM) overnight. CD80 and CD83 expression in
gated CD11c+HLA-DR+ population was analyzed by ﬂow cytometer. Data are representative of two independent experiments showing similar results.
4934 A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938series do indeed activate the transgenic human TLR4/MD-2
complex to a greater extent relative to mouse TLR4/MD-2
(Fig. 4C, D, and E).The innate immune receptor that is responsible for the physio-
logical recognition of LPS is TLR4, in association with MD-2.13,14
The structural basis of receptor speciﬁcity and of the mechanism
Figure 4. Compound 1a is more potent in human cells than in murine cells. (A) CellSensor RAW264.7 or CellSensor THP-1 cells were incubated with graded concentrations
of 1a. The levels of NF-jB activation were normalized with LPS and expressed as percent activation. The average response ratio of LPS (5 ng/mL) in RAW and THP-1
CellSensor cells was 6.5 ± 0.17 and 3.27 ± 0.67, respectively. (B and C) Murine BMDC (B) or hPBMC (C) were stimulated with graded concentrations of 1a overnight. Murine
IL-6 or hIL-8 in the culture supernatant was determined by ELISA. (D and E) BMDM from mice expressing the human TLR4/MD-2 complex were incubated with compound 1a
(5 lM) or LPS and supernatants assayed for IL-6 (D) and IP-10 (E). Data shown are mean ± SEM of triplicates and representative of two independent experiments showing
similar results.
A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938 4935of activation by LPS have recently been elucidated by determining
the crystal structure of the TLR4/MD-2-LPS complex at 3.1 Å
resolution.15 Binding of agonistic ligands, such as LPS, cause
dimerization of the extracellular domains to form a TLR4/MD-2-
LPS complex. Like the extracellular domains of other TLRs, TLR4
contains leucine-rich repeats and adopts a characteristic horse-
shoe-like shape. MD-2 is non-covalently bound to the side of the
horseshoe ring and also directly interfaces with the ligand. MD-2
has a b-cup fold structure composed of two antiparallel-b sheets
forming a large hydrophobic pocket for ligand binding. LPS binds
to this pocket and directly mediates dimerization of the twoFigure 5. Predicted binding mode of compound 1a to human TLR4/MD-2 complex. The
residues of TLR-4 which signiﬁcantly increase the probability and stability of binding.TLR4/MD-2 complexes. TLR4 can be activated by structurally
diverse LPS molecules, which have been predicted to occupy this
pocket in MD-2.
The 4-aminoquinazoline hit compound discovered in the
present study was also thought to bind to the TLR4/MD-2 complex.
Accordingly, we examined the predicted binding mode(s) of
compound 1a to the crystal structure of the human TLR4/MD-2
complex (PDB: 3fxi) using the docking program HEX,16 and
AMPAC17 for optimization of the compound conformation. We
selected the best conﬁgurations of 1a bound to this complex based
on molecular surface shape complementarity and the mostcompound has attractive interactions with the seven residues of MD-2, and three
4936 A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938favorable intermolecular energy of interactions. Interestingly, the
best docking position for 1a was within the LPS pocket.15
Figure 5 shows the predicted binding mode of compound 1a in
the TLR4/MD-2 model, while the set of binding interactions that
may keep the compound in the MD-2 pocket bound to both TLR4
and MD-2 is depicted in Figure 6. There is a set of possible hydro-
gen bonds formed by the residues Gln436 and Glu439 of TLR4 and
Arg90 of MD-2. Noteworthy is the interaction of the two polar nitro
oxygens of the compound with the backbone nitrogens of Ile124
and Lys122 of the MD-2 protein. The positive charge of the
Lys122 provides a signiﬁcant attractive force for a nitro oxygen
in the human TLR4/MD-2 complex, whereas in the mouse complex,
this residue is replaced by glutamic acid. Thus, the negative charge
of the Glu122 in the mouse MD-2 causes an increase in repulsion
energy as it encounters the negative oxygens of the nitro function
in the compound and is likely at least partially responsible for the
decreased activity of the compound in mouse cells relative to
human cells. Also, there are several hydrophobic interactions with
MD-2, involving residues Leu87, Phe126, Ile124, Phe121, and
Phe119. Taken together, such interactions of the compound with
two proteins can improve the free energy of complex formation
by approximately 10 kcal/mol.
The above data indicate that compound 1a activates NF-jB
preferentially through the human TLR4/MD-2 complex rather than
through the murine TLR4/MD-2 complex, in a CD14 independent
manner. Considering this selective activity, it was thought that
compound 1amight serve as a useful chemical probe to investigate
TLR4/MD-2 receptor-ligand speciﬁcity. Hence, compound 1a pro-
vided a starting point for structure-activity studies.
The primary HTS library contained a very small family of com-
pounds in the 4-aminoquinazoline class and therefore provided
only a limited indication of structural features important for
activation of NF-jB. Substitutions at three sites were ﬁrst under-
taken to probe structural requirements and limitations with
respect to optimization of cytokine induction in hPBMC and
induction of NF-jB activation in TLR4 reporter cells (Table 1).
While keeping all other structural features of hit compound 1a
constant, we prepared a series of derivatives with variations atFigure 6. Predicted binding interactions of compound 1a with hTLR4/MD-2 complex (PD
of the compound position in the pocket. Purple—TLR4, yellow—MD-2.(1) the phenoxy moiety; (2) the nitro group; and (3) the ester
function. The synthesis began with construction of the appropri-
ately substituted nitroaniline as shown in Scheme 1. Trinitroben-
zene was carefully reacted with appropriately substituted
phenols according to the general method of Shevelev et al.18 to
provide the corresponding dinitrophenoxy compounds 2a–j, and
k. The dinitro intermediates were then partially reduced to the
corresponding nitroanilines (3a–j, and k) using ammonium
sulﬁde. These nitroanilines were condensed with the chloroqui-
nazoline compound 419 to provide the corresponding substituted
4-aminoquinazolines 1a–j and k. Thus, we re-synthesized the ori-
ginal hit compound 1a by this method along with a variety of
phenoxy derivatives substituted with alkyl and halogen groups.
As indicated in Table 1, the results from assays using the TLR4
reporter cells and hPBMC suggest that when the phenoxy group
in 1a is substituted in the ortho position by groups such as chloro
(1f), bromo (1g), iodo (1h), or methyl (1b), the activity is
enhanced relative to hydrogen (values in the Table are normal-
ized to LPS positive control = 100). However, if the alkyl group
is larger than methyl, such as ethyl (1e), a substantial loss of
activity is observed. Likewise, if the aryloxy group is larger than
phenoxy, such as naphthyloxy (1k), a loss of activity is also
encountered. The importance of the nitro group in compound
1a for cytokine induction was investigated by reduction of the
nitro to the primary amine compound (5a) using Raney nickel
which resulted in complete loss of activity. Next the ester func-
tion was modiﬁed to include conversion to the free carboxylic
acid (6a, 7a, 7g) and then to the carboxamide (9a) and the N-eth-
ylcarboxamide (8a). Other esters were formed including the
methyl (10a), isopropyl (11a) and isoamyl (12a) esters. The com-
pound that combines the features of the ortho-bromophenoxy
moiety and the isopropyl ester (13g) was also prepared.
Besides the necessity of a nitro group in the aminophenyl moi-
ety for TLR4 binding activity, a comparison in hTLR4 reporter cells
of selected compounds from the SAR studies for modiﬁcations at
the ortho-position of the phenoxy moiety suggests that lower alkyl
or halogen groups at this position are favored for activity (Fig. 7A).
Likewise, for the ester function at the 2-position of the quinazolineB ID: 3fxi). The set of H-bond and hydrophobic interactions supports the prediction
Table 1
Activity of substituted 4-aminoquinazolines in hTLR4 transfectoma and primary
human PBMC
Compd R1 R2 (o) R3 (o2) R4 (m) R5 (p) R6 hTLR4a PBMCb HepG2
0.5 lM 0.5 lM MTTc
LPS 100 100 100.9
1a NO2 H H H H OC2H5 49.1 22.2 93.5
1b NO2 CH3 H H H OC2H5 45.5 20.5 96.7
1c NO2 H H CH3 H OC2H5 14.5 5.8 109.9
1d NO2 H H H CH3 OC2H5 0.5 0.4 108.8
1e NO2 Et H H H OC2H5 4.2 3.2 98.9
1f NO2 Cl H H H OC2H5 73.9 27.3 107.4
1g NO2 Br H H H OC2H5 79.0 35.6 90.8
1h NO2 I H H H OC2H5 65.5 34.2 93.8
1i NO2 CF3 H H H OC2H5 58.7 26.5 67.1
1j NO2 CH3 CH3 H H OC2H5 0.6 0.0 106.3
1k NO2 H H * * OC2H5 0.8 0.0 111.4
5a NH2 H H H H OC2H5 0.6 0.3 106.1
6a NH2 H H H H OH 1.1 0.3 105.0
7a NO2 H H H H OH 0.6 0.5 84.5
7g NO2 Br H H H OH 1.6 0.0 96.3
8a NO2 H H H H NHC2H5 2.2 1.5 107.4
9a NO2 H H H H NH2 0.0 0.3 78.4
10a NO2 H H H H OCH3 0.4 0.2 116.4
11a NO2 H H H H O-Isopropyl 7.4 2.1 65.6
12a NO2 H H H H O-Isoamyl 8.4 2.2 63.4
13g NO2 Br H H H O-Isopropyl 67.8 19.2 106.5
* 2-Naphthol instead of phenol.
a Average Quantiblue OD630 of hTLR4 HEK Blue cells incubated with LPS
(100 ng/mL) was 1.22 ± 0.17.
b Average IL-8 release by 100 ng/mL LPS was 25.9 ± 5.6 ng/mL.
c MTT assay data (compounds tested at 10 lM) were normalized with OD570–650
of vehicle treatment in the related experiments. The average MTT reading for
HepG2 cells treated with vehicle was 1.326 ± 0.294.
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Figure 7. Representative results of substituted 4-aminoquinazolines using hTLR4 tran
incubated with graded concentrations of 1a or indicated SAR compounds (A: 1e and 1g, B
assay. (C and D) Human PBMC from two independent donors were stimulated with 0.5 o
shown are mean ± SEM of triplicate and represents two to three experiments showing s
A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938 4937ring, the ethyl ester is preferred over a smaller or larger alkyl group
(Fig. 7B). In primary hPBMC, the same trends are apparent, partic-
ularly at the lower, more physiologically relevant concentration of
0.5 lM (Fig. 7C and D).
In the course of an HTS designed to identify activators of innate
immunity, a series of substituted 4-aminoquinazolines was discov-
ered as selective TLR4 ligands. Small molecules of this class are
unique among TLR4 activators in that they are ‘non-lipid-like’.
Structure–activity evaluation in both mouse and human cells
revealed that this series of small molecules activates the human
TLR4/MD-2 complex more potently than the corresponding mouse
complex and this activation was observed to be MD-2-dependent
and CD14-independent. Interestingly, a recent report describes a
natural product, Euodenine A,20 that activates human TLR4 more
potently than the corresponding mouse receptor and shares a sim-
ilar immunologic proﬁle with the 4-aminoquinazolines described
here. The 4-aminoquinazolines species preference phenomenon
could be explained, at least in part, by the observation that certain
amino acid residues of the MD-2 proteins of the TLR4/MD-2 com-
plex vary in mouse versus human at critical interaction binding
sites for the 4-aminoquinazoline compounds. Indeed, a simple
change in residue 122 of MD-2 from Lys in human to Glu in mouse
is predicted to reverse the electrostatic inﬂuence of binding of the
nitro oxygen(s) of, for example, the active compound 1a. The result
is an attractive force in the human complex for the compound, but
a repulsive force at the same site in the mouse complex.
Initial SAR studies revealed several ﬁndings. First, the nitro
group on the phenylamino moiety is essential for activity since
reduction to amino abrogated the activity. Indeed, computational
studies showed that interactions at the predicted binding site of
MD-2 for the nitro compound were much more favorable (by as
much as 6.1 kcal/mol total energy improvement in interaction
energy) compared to the corresponding amino compound.
Aromatic or heteroaromatic nitro groups are well known in drug
design. Examples are the 5-nitrofurans and 2- and 5-nitroimidaz-
oles. These drugs are used as therapeutic agents against a variety
of protozoan and anaerobic bacterial infections in humans and ani-
mals.21 However, the compounds reported here represent the ﬁrst
known class of nitro-containing small molecules that can activate a
human innate immune receptor. Second, a small alkyl or halogen
group at the ortho position of the phenoxy moiety enhances10-2 10-1 100 101
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4938 A. Nour et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4931–4938activity. Third, a lower alkyl ester at the 2-position of the quinazo-
line ring appears to be favored for activity, while compounds
having the corresponding carboxylic acid form or unsubstituted
amide are not active. Interestingly none of the substitutions
increased the activity of the compound to preferentially stimulate
murine rather than human cells, a ﬁnding opposite from that
observed with certain other small molecule TLR4 ligands, pyrimi-
do[5,4-b]indoles, that were also discovered in the same HTS pro-
cess.5 Lead optimization studies to improve the activity of the
compounds using computational methods are currently underway
in our laboratories. Optimized lead compounds in the 4-aminoqui-
nazoline class that stimulate innate immune cells with minimal
toxicity may be useful as adjuvants or immunotherapeutic agents.
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